Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

New York State Common Retirement Fund trimmed its Regeneron stake by 5% in Q1, selling over 6,800 shares worth millions.

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it ...

Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

Regeneron Pharmaceuticals Inc. research and ratings by Barron's. View RGO revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals Inc. stock grades by Barron's. View REGN fundamental and sentiment analysis powered by MarketGrader.

We recently published Jim Cramer’s Fresh 14 Stocks & Thoughts About Market Performance. Cencora, Inc. (NYSE:COR) is one of ...

This was the stock's fourth consecutive day of gains.